MX2018010958A - Vacuna para virus de zika atenuado vivo. - Google Patents
Vacuna para virus de zika atenuado vivo.Info
- Publication number
- MX2018010958A MX2018010958A MX2018010958A MX2018010958A MX2018010958A MX 2018010958 A MX2018010958 A MX 2018010958A MX 2018010958 A MX2018010958 A MX 2018010958A MX 2018010958 A MX2018010958 A MX 2018010958A MX 2018010958 A MX2018010958 A MX 2018010958A
- Authority
- MX
- Mexico
- Prior art keywords
- virus
- attenuated
- zikv
- vaccines
- zika
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
- C12N2770/24162—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente descripción se relaciona a virus de Zika atenuados y vacunas, virus de Zika quiméricos atenuados y vacunas, y a composiciones inmunogénicas multivalentes que comprenden vacunas para Zika y vacunas para otros flavivirus. El virus de Zika quimérico incluye una primera secuencia de nucleótidos que codifica por lo menos una proteína estructural de un virus de Zika (ZIKV), una segunda secuencia de nucleótidos que codifica por lo menos una proteína no estructural de un primer flavivirus, y una tercera secuencia de nucleótidos de una región (3´) no traducida de un segundo flavivirus. Las composiciones inmunogénicas multivalentes comprenden una vacuna para ZIKV atenuado o una vacuna para ZIKV quimérico atenuado (o su combinación) junto con uno o más de un primer virus atenuado que es inmunogénico contra el serotipo (1) de dengue, un segundo virus atenuado que es inmunogénico contra el serotipo (2) de dengue, un tercer virus atenuado que es inmunogénico contra el serotipo (3) de dengue, y un cuarto virus atenuado que es inmunogénico contra el serotipo (4) de dengue. La presente descripción además se relaciona a métodos para inducir respuestas inmunes, así como prevenir o tratar infecciones de ZIKV, y en ciertas modalidades, la prevención combinada o tratamiento de ZIKV y otro flavivirus, por ejemplo, virus de dengue.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662307170P | 2016-03-11 | 2016-03-11 | |
PCT/US2017/021989 WO2017156511A1 (en) | 2016-03-11 | 2017-03-11 | Live attenuated zika virus vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2018010958A true MX2018010958A (es) | 2019-02-07 |
Family
ID=58428363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2018010958A MX2018010958A (es) | 2016-03-11 | 2017-03-11 | Vacuna para virus de zika atenuado vivo. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20190194260A1 (es) |
EP (1) | EP3426292A1 (es) |
JP (1) | JP2019511221A (es) |
KR (1) | KR20180127397A (es) |
CN (1) | CN109152828A (es) |
AU (1) | AU2017230112A1 (es) |
BR (1) | BR112018068342A2 (es) |
CA (1) | CA3016697A1 (es) |
CO (1) | CO2018010874A2 (es) |
MX (1) | MX2018010958A (es) |
WO (1) | WO2017156511A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018010789A1 (en) | 2016-07-13 | 2018-01-18 | Humabs Biomed Sa | Novel antibodies specifically binding to zika virus epitopes and uses thereof |
WO2018129160A1 (en) | 2017-01-06 | 2018-07-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Live attenuated flavivirus vaccines and methods of using and making same |
WO2019042555A1 (en) | 2017-08-31 | 2019-03-07 | Humabs Biomed Sa | MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF |
GB201716307D0 (en) * | 2017-10-05 | 2017-11-22 | Univ Leuven Kath | Chimeric yellow fever zika virus strain |
US11739348B2 (en) | 2017-11-10 | 2023-08-29 | The Research Institute At Nationwide Children's Hospital | Recombinant vectors encoding Zika virus protein subunits |
EP3846848A4 (en) * | 2018-09-04 | 2022-07-06 | The Board of Regents of the University of Texas System | DNA PLASMID INITIATED LIVE VACCINES FOR PLUS-POLARITY SINGLE STRAND RNA VIRUS |
CA3145401A1 (en) * | 2019-06-25 | 2020-12-30 | Codagenix Inc. | Attenuated dengue viruses |
WO2022182835A1 (en) * | 2021-02-26 | 2022-09-01 | Duke University | Compositions for and methods of improving gene therapy |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1978027B1 (en) | 2000-02-10 | 2012-07-25 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Full-length infectious cDNA clones of tick borne flavivirus |
CA3114957C (en) * | 2001-05-22 | 2022-02-08 | Stephen S. Whitehead | Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses |
CA2903126C (en) | 2002-01-10 | 2020-03-24 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Construction of west nile virus and dengue virus chimeras for use in a live virus vaccine to prevent disease caused by west nile virus |
EP3763382A1 (en) | 2002-05-03 | 2021-01-13 | The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services | Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1, 2, 3, and 4, or antigenic chimeric dengue viruses 1, 2, 3, and 4 |
US7622113B2 (en) | 2003-12-08 | 2009-11-24 | The United States Of America As Represented By The Department Of Health And Human Services | Monoclonal antibodies that bind or neutralize dengue virus |
US7851194B2 (en) | 2004-06-14 | 2010-12-14 | The United States Of America As Represented By The Department Of Health And Human Services | West Nile viruses with mutations in the 3′ terminal stem and loop secondary structure for use as live virus vaccines |
SI2589602T1 (sl) | 2006-08-15 | 2016-08-31 | The Government of the U.S.A., as repr. by the Secretary, Dept. of Health & Human Services, the Nat. Inst. of Health Office of Technology Transfer | Razvoj sestavin cepiva proti virusu denge |
US20100316670A1 (en) | 2007-06-14 | 2010-12-16 | Blaney Joseph E | Chimeric sle/dengue type 4 antigenic viruses |
US20120294889A1 (en) * | 2010-11-12 | 2012-11-22 | Paxvax, Inc. | Chimeric Flavivirus Vaccines |
-
2017
- 2017-03-11 KR KR1020187029244A patent/KR20180127397A/ko not_active Application Discontinuation
- 2017-03-11 EP EP17714066.2A patent/EP3426292A1/en not_active Withdrawn
- 2017-03-11 MX MX2018010958A patent/MX2018010958A/es unknown
- 2017-03-11 CN CN201780028836.4A patent/CN109152828A/zh active Pending
- 2017-03-11 JP JP2018547931A patent/JP2019511221A/ja not_active Withdrawn
- 2017-03-11 AU AU2017230112A patent/AU2017230112A1/en not_active Abandoned
- 2017-03-11 CA CA3016697A patent/CA3016697A1/en not_active Abandoned
- 2017-03-11 BR BR112018068342A patent/BR112018068342A2/pt not_active IP Right Cessation
- 2017-03-11 WO PCT/US2017/021989 patent/WO2017156511A1/en active Application Filing
- 2017-03-11 US US16/083,652 patent/US20190194260A1/en not_active Abandoned
-
2018
- 2018-10-10 CO CONC2018/0010874A patent/CO2018010874A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3016697A1 (en) | 2017-09-14 |
AU2017230112A1 (en) | 2018-10-04 |
CO2018010874A2 (es) | 2018-10-22 |
BR112018068342A2 (pt) | 2019-01-15 |
WO2017156511A1 (en) | 2017-09-14 |
KR20180127397A (ko) | 2018-11-28 |
US20190194260A1 (en) | 2019-06-27 |
JP2019511221A (ja) | 2019-04-25 |
EP3426292A1 (en) | 2019-01-16 |
CN109152828A (zh) | 2019-01-04 |
WO2017156511A8 (en) | 2018-09-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018010958A (es) | Vacuna para virus de zika atenuado vivo. | |
EA201800108A1 (ru) | Вакцинные композиции для профилактики абровирусных инфекций | |
MX2018014573A (es) | Vacuna contra el virus del zika. | |
PH12021550479A1 (en) | Dengue vaccine unit dose and administration thereof | |
WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
EA201892735A1 (ru) | Состав вакцины против hiv | |
ECSP18026090A (es) | Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue | |
MX2018015506A (es) | Vacuna contra virus de bronquitis infecciosa. | |
PH12015000376A1 (en) | Hand, foot, and mouth vaccines and methods of manufacture and use thereof | |
CL2022002412A1 (es) | Vacuna | |
PH12015502666A1 (en) | Dengue virus vaccine compositions and methods of use thereof | |
BR112017028212A2 (pt) | vacinação concomitante contra dengue e febre amarela | |
GEP20237539B (en) | Formulations of dengue virus vaccine compositions | |
PH12018501750A1 (en) | Porcine reproductive and respiratory syndrome vaccine virus | |
BR112018074910A2 (pt) | composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito | |
NZ631012A (en) | Compositions and methods for live, attenuated alphavirus formulations | |
CR20170280A (es) | Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas | |
EA202191147A1 (ru) | Вакцина виб h52 с гетерологичным шиповидным белком | |
BR112016029201A2 (pt) | vírus do oeste do nilo/dengue quiméricos e métodos de uso | |
EA201790776A1 (ru) | Комбинированные композиции длительного действия и способы лечения гепатита с | |
EA202090236A1 (ru) | Иммуногенные композиции senecavirus a и способы с ними | |
PH12018501107A1 (en) | Live virus having a bank of dengue virus attenuated strains, and a dengue vaccine containing same as antigens | |
AR101932A1 (es) | Agente con propiedades antivirales para prevenir o tratar peces expuestos a un virus de la familia birnaviridae | |
WO2019113285A3 (en) | Zika vaccines and methods of use |